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An increased incidence of cancer in patients with dermatomyositis
(DM) (Hidano et al, 1992; Sigurgeirsson et al, 1992; Rose et al,
1994; Selvaag et al, 1994; Zantos et al, 1994; Airio et al, 1995;
Chow et al, 1995; Maos et al, 1998) and polymyositis (PM)
(Sigurgeirsson et al, 1992; Zantos et al, 1994; Chow et al, 1995;
Maos et al, 1998) has been reported in many studies, though with
wide variations in the estimated risks. A few studies did not find
an excess risk of cancer (Lakhanpal et al, 1986; Manchul et al,
1998) although these were hospital-based case–control studies of
limited size. The increased risk has been reported to be greater in
patients with DM and particularly among older (> 50 years)
patients (Airio et al, 1995), and to decrease with time since the first
DM or PM diagnosis (Chow et al, 1995). The present study was
designed to estimate the risk of cancer among a population-based
cohort of patients with DM or PM in Scotland, in relation to age at,
and time since diagnosis, and to assess the implications for follow-
up of patients with DM or PM. 
MATERIALS AND METHODS 
Patients 
The Information and Statistics Division (ISD) of the National
Health Service in Scotland has linked (at the time of analysis),
using probability matching, information on all hospital inpatient
episodes occurring between 1 January 1981 and 31 January 1998
in Scotland to death records for the same period and cancer
registry records for patients diagnosed with cancer (ICD-9:
140–208) between 1980 and 1996 (Kendrick and Clarke, 1993).
For this study all records for patients with an initial diagnosis of
DM (ICD-9: 710.3) or PM (ICD-9: 710.4) between 1982 and 1996
were selected from the linked database, giving a population-based
dataset covering 15 years. Follow-up was until the end of 1996
because, at the time of analysis, cancer registration records were
not complete beyond this date. The starting date was restricted to
1982 to reduce the erroneous inclusion of cases who had an earlier
diagnosis of DM or PM. Additionally, the selected patients with
DM or PM were probability matched to the cancer registry data-
base from 1968 to 1979 to obtain information on all antecedent
cancers in these patients. For patients with a diagnosis of both 
DM and PM (n = 32), only the earliest diagnosis was included.
Non-melanoma skin cancers were excluded as data are likely to be
less complete for these cancers because they are relatively
common and usually non-fatal, and do not usually involve hospital
admission.
Statistical analysis
Persons-years at risk were calculated from the date of admission to
hospital with a first diagnosis of DM or PM, to either the date of
death or 31 December 1996, whichever occurred first. The
observed numbers of cancer cases were compared with those
expected based on sex-, age- (five year age band to 85+) and
period- (1982–86, 1987–91, 1992–96) specific incidence rates for
Scotland. No attempt was made to adjust for socio-economic
status as DM or PM showed no evidence of a socio-economic
gradient (data not shown but available on request). The Scottish
cancer incidence rates were calculated from (1) all incident cases
and (2) only first malignancies. The standardized incidence ratio
(SIR) was defined as the ratio of the observed to expected number
of cases and the 95% confidence interval was estimated assuming
that the observed number of cases followed a Poisson distribution.
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(1)For estimation of the overall risk of cancer following DM or
PM diagnosis – all patients with a malignancy diagnosed
concurrently or after the first DM or PM diagnosis were
included even if they had a previous cancer diagnosis;
observed numbers were compared to those expected based on
all incident cases in Scotland. Only the first cancer occurring
concurrently or after the first DM or PM diagnosis was
included. 
(2)For estimation of the risk of cancer in patients with no sign of
cancer at DM or PM diagnosis – all patients with an
antecedent cancer or cancer diagnosed within 3 months of the
first DM or PM diagnosis were excluded. The remaining
observed cases were compared to expected numbers based on
the incidence of first malignancies in Scotland; this was also
done in relation to age at, and time since, diagnosis of DM or
PM. Only the first cancer occurring after the first DM or PM
diagnosis was included. 
RESULTS 
Overall, 705 patients with an initial diagnosis of DM (n = 286) or
PM (419) between January 1982 and December 1996 were identi-
fied. There were 272 men and 433 women, of whom 44 (6%) were
aged under 15 years, 167 (24%) were between the ages of 15 and
44 years, 414 (59%) were aged 45 to 74, and 80 (11%) were aged
75 years or older. The cancer history of these patients can be seen
in Figure 1, with the incidence of cancer being distributed evenly
both before and after the diagnosis of DM or PM. A large number
of cancers were diagnosed at the same time or within 3 months of
the DM or PM diagnosis. The numbers reduced in both directions
as time from DM or PM diagnosis increased. 
Dermatomyositis 
Among patients with a first diagnosis of DM (97 men and 189
women), cancer was (or had previously been) diagnosed in 77
(27%) patients. 
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Table 1 Observed (Obs) numbers of cancers and standardized incidence ratios (SIR) among patients with DM or PM diagnosed in Scotland 1982–1996 
Type
Cancer inclusion Time since DM/PM
Overall Males Females 
criteria diagnosis Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI 
Dermatomyositis First cancera Concurrently or afterc 50 7.7 (5.7, 10.1) 20 9.2 (5.6, 14.1) 30 6.9 (4.7, 9.9) 
Afterd 20 3.3 (2.0, 5.1) 5 2.5 (0.8, 5.9) 15 3.7 (2.1, 6.1) 
Any cancerb Concurrently or afterc 51 5.8 (4.4, 7.7) 20 7.4 (4.5, 11.4) 31 5.2 (3.5, 7.3) 
Afterd 22 2.7 (1.7, 4.1) 5 2.0 (0.7, 4.8) 17 3.0 (1.7, 4.8) 
Polymyositis First cancera Concurrently or afterc 40 2.1 (1.5, 2.9) 12 1.3 (0.7, 2.2) 28 3.0 (2.0, 4.4) 
Afterd 29 1.6 (1.1, 2.4) 8 0.9 (0.4, 1.8) 21 2.4 (1.5, 3.7) 
Any cancerb Concurrently or afterc 43 1.8 (1.3, 2.4) 13 1.1 (0.6, 1.9) 30 2.5 (1.7, 3.5) 
Afterd 32 1.4 (1.0, 2.0) 9 0.8 (0.4, 1.5) 23 2.0 (1.3, 3.0) 
aOnly first primary malignancies are included in the calculation of both the observed and expected. bIncluding second cancers in patients who had a cancer prior
to the DM or PM diagnosis. cCancers diagnosed at the same time or after the DM or PM diagnosis. dCancers diagnosed at least 3 months after the DM or PM
diagnosis. 
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Figure 1 Occurrence of cancer (only first primary malignancies are included) around DM or PM diagnosis A first malignancy was diagnosed concurrently or after the DM
diagnosis in 50 patients giving a standardized incidence ratio (SIR)
of 7.7 (95% confidence interval 5.7–10.1) compared to that
expected based on the incidence of first malignancies in Scotland
as a whole. When cancers diagnosed in the first 3 months
following diagnosis were excluded (under the assumption that they
are concurrent diagnoses made while the patient was under height-
ened surveillance) there was a smaller, but still significant, 3-fold
increased risk with an SIR of 3.3 (2.0–5.1) (Table 1). The increase
is seen in both men and women. When individual cancers were
analysed, a significant increase was seen for a number of cancers,
in particular, a 5-fold increased risk for lung, 12-fold for cervical,
and 10-fold for ovarian cancer (Table 2). 
For all first malignancies combined there was a very high
increased risk (SIR 65.6) in the first 3 months after diagnosis,
elevated risks which were bordering on or statistically significant
for the following periods up to 2 years, and then elevated but non-
significant risks thereafter (Figure 2). The increased risks were
significant in the 45–74 age group, with SIRs of 4.8 (95% CI
0.6–17.4), 3.6 (2.0–5.9) and 2.1 (0.4–6.1) in the age groups 15–44,
45–74 and 75+, respectively. No cancers were seen in the 35 chil-
dren (aged < 15) recorded as having DM. 
Polymyositis 
Among patients with a first diagnosis of PM (175 men and 244
women), cancer was (or had previously been) diagnosed in 71
(17%) patients. 
A first malignancy was diagnosed concurrently or after the PM
diagnosis in 40 patients (SIR 2.1, 1.5–2.9). When cancers diag-
nosed in the first 3 months following diagnosis were excluded the
SIR was still significantly high (SIR 1.6, 1.1–2.4) (Table 1). The
increase was mainly seen in women with a non-significant excess
for men which disappeared when the cancers diagnosed within 3
months of PM are excluded. The number of observed cancers were
small when individual cancers were analysed, however there was a
significant increase in risk for Hodgkin’s disease (SIR 32.5,
3.9–117.2) (Table 2). 
For all first malignancies combined there was a high increased
risk (SIR 12.0) in the first 3 months after diagnosis; subsequently
the risk reduced leaving a small, mainly non-significant excess
thereafter (Figure 2). The increased risks were significant in the
15–44 age group, with SIRs of 8.9 (2.4–22.8), 1.5 (0.9–2.4) and
1.3 (0.5–2.6) in the age groups 15–44, 45–74 and 75+, respec-
tively. No cancers were seen in the 9 children recorded as having
PM. 
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Table 2 Observed (Obs) number of cancers and standardized incidence ratios (SIR) of cancers diagnosed among patients with DM or PM in Scotland
1982–1996a
Type
ICD9
Cancer Concurrently or afterb Afterc
code Obs SIR 95% CI Obs SIR 95% CI 
DM 150 Oesophagus 1 6.2 (0.2, 34.4) 0 
151 Stomach 3 10.0 (2.1, 29.2) 0 
153 Colon 7 12.8 (5.1, 26.3) 1 2.0 (0, 10.9) 
162 Lung 19 15.6 (9.4, 24.3) 6 5.3 (2, 11.6) 
174 Breast (women) 3 2.7 (0.6, 7.9) 3 2.8 (0.6, 8.3) 
180 Cervix uteri 2 11.4 (1.4, 41.1) 2 11.9 (1.4, 43) 
183 Ovary 2 9.1 (1.1, 32.7) 2 9.6 (1.2, 34.5) 
185 Prostate 1 3.7 (0.1, 20.8) 1 4.2 (0.1, 23.1) 
188 Bladder 1 3.2 (0.1, 18.1) 0 
196–199 Secondary and unspecified malignancy 6 18.5 (6.8, 40.4) 3 10.0 (2.1, 29.1) 
201 Hodgkin’s disease 1 28.4 (0.7, 157.9) 1 29.8 (0.8, 165.9) 
202 Non-Hodgkin’s lymphoma 2 13.3 (1.6, 48) 1 7.1 (0.2, 39.8) 
PM 140 Lip 1 17.1 (0.4, 95.1) 1 17.8 (0.4, 99) 
141 Tongue 1 15.4 (0.4, 85.9) 1 16.2 (0.4, 90.4) 
143 Gum 1 71.5 (1.8, 398.3) 1 75.2 (1.9, 418.7) 
153 Colon 1 0.6 (0, 3.4) 1 0.6 (0, 3.6) 
154 Rectum 2 2.4 (0.3, 8.7) 2 2.5 (0.3, 9.1) 
155 Liver 1 6.7 (0.2, 37.3) 0 
156 Gall bladder 1 8.4 (0.2, 47) 1 8.8 (0.2, 49.1) 
162 Lung 8 1.9 (0.9, 3.8) 5 1.3 (0.4, 3) 
172 Malignant melanoma of skin 1 3.5 (0.1, 19.4) 1 3.7 (0.1, 20.4) 
174 Breast (women) 5 2.3 (0.7, 5.4) 5 2.4 (0.8, 5.6) 
182 Corpus uteri 1 3.6 (0.1, 20) 1 3.8 (0.1, 21) 
183 Ovary 1 2.3 (0.1, 12.6) 1 2.4 (0.1, 13.2) 
185 Prostate 4 3.2 (0.9, 8.3) 2 1.7 (0.2, 6.2) 
189 Kidney 1 2.7 (0.1, 15.2) 0 
191 Brain 1 4.9 (0.1, 27.5) 0 
193 Thyroid 1 15.2 (0.4, 84.7) 0 
196–199 Secondary and unspecified malignancy 3 3.1 (0.6, 9) 3 3.2 (0.7, 9.4) 
201 Hodgkin’s disease 2 31.0 (3.8, 112) 2 32.5 (3.9, 117.2) 
202 Non-Hodgkin’s lymphoma 2 5.0 (0.6, 18.1) 1 2.6 (0.1, 14.7) 
203 Multiple myeloma 2 8.6 (1, 31.2) 1 4.5 (0.1, 25.2) 
aOnly first primary malignancies are included in the calculation of both the observed and expected. bCancers diagnosed at the same time or after the DM or PM
diagnosis. cCancers diagnosed at least 3 months after the DM or PM diagnosis. DISCUSSION 
We evaluated the association between DM and PM and a subse-
quent cancer in a large population-based cohort and confirmed an
increased risk of several types of cancer. In particular, there was a
strong association between DM and lung, cervical, and ovarian
cancers; and between PM and Hodgkin’s disease. 
It should be noted that, although some of the risks found are
large, they are based on small numbers of excess cases, and are the
product of multiple tests of statistical significance. Nevertheless,
other population-based studies have also found an increased risk
for cancers of the lung, female genital organs and ovary among
patients with DM (Sigurgeirsson et al, 1992; Airio et al, 1995;
Chow et al, 1995). The results for PM and cancer are not as well
supported: one study suggests that patients may be prone to certain
tumours, such as lymphoma, myeloma or leukaemia due to a
compromised immune state, or as a result of immuno-suppressive
or cytotoxic therapy (Chow et al, 1995). However, another study
failed to find a cancer excess among DM patients treated with
cytotoxic drugs (Airio et al, 1995). 
It is likely that some of the excess cancer occurrence reported
among patients with DM and PM reflects intensive investigation
due to the known association between DM or PM and cancer
(Lakhanpal et al, 1986; Manchul et al, 1998). Its effects are prob-
ably most evident around the time of diagnosis of DM or PM
(Figure 1). As an attempt to account for this surveillance bias, risk
of cancer was studied, excluding those diagnosed within 3 months
of the DM or PM diagnosis, and we found a 3-fold increased 
risk of cancer for DM patients and a 1.6-fold increased risk for PM
patients (Table 1). 
In line with a similar study from Denmark (Chow et al, 1995),
we restricted our analysis to first cancers arising after the (first)
diagnosis of DM or PM. This avoids the confounding effect of
cancer itself being a risk factor for subsequent cancers, through
genetic susceptibility, shared risk factors, or the effects of 
therapy. However, it means that our estimates of risk may be
conservative. 
Some patients may have been included erroneously as having a
first diagnosis of DM or PM when they actually had a previous diag-
nosis prior to 1981. This would have the effect of over-estimating
the risk of cancer due to under-estimation of the person-years of
observation. From the initial data set of 769 cases diagnosed over
the period 1981–1996, 31 patients had 2 admissions for DM and/or
PM (15 within one year, 11 within 1–5 years, and 5 greater than 5
years apart). From our analysis, restricted to DM and PM patients
diagnosed from 1982 onwards, we estimate that not more than 10
(1%) patients will have been wrongly included as first diagnoses. 
The results of our study relate only to patients with DM or PM
who are hospitalized at some stage of their disease, although the
diagnosis of DM or PM is likely to be more secure in such
patients. The risk of cancer will probably be either similar or lower
in patients who are not hospitalized. If any bias exists, therefore,
the effect will have been to over-estimate the risk of cancer with
respect to all patients with DM or PM. 
Although there is limited published evidence about the quality
of hospital discharge data in Scotland, a recent study estimated
that, during the early to mid 1990s, the overall accuracy of coding
diagnosis approached 90% (Harley and Jones, 1996). The quality
of cancer registry data in Scotland is also believed to be high, both
in terms of accuracy (Brewster et al, 1994) and ascertainment
(Brewster et al, 1997). The method of record linkage used in
Scotland is estimated to result in mismatched records in less than
2% of cases (Kendrick and Clarke, 1993). Although we are unable
to quantify losses to follow-up through migration, they are
unlikely to represent a major source of bias among this group of
patients and would result in an under-estimation of risk. 
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Figure 2 Temporal trends in risk of cancer (only first primary malignancies are included in the calculation of both the observed and expected) after DM or PM
diagnosis In a similar study in Sweden (Sigurgeirsson et al, 1992) the
validity of hospital diagnoses of DM and PM was reviewed in a 9%
sample of hospital medical records. Only 7% of this sample were
judged probably not to have either condition. In contrast, another
similar study in Finland (Airio et al, 1995) assessed the validity of
DM and PM diagnoses in hospital episode records by checking
manually all available medical records, and found that 33% of their
cases were misclassified. In our study, it was not feasible to check
the DM and PM diagnoses manually. We found that 11% of the
patients in our study diagnosed during 1982–90 had a subsequent
in-patient diagnosis of conditions, such as polymyalgia rheumatica,
which the Finnish study identified as leading to misclassification.
(We restricted our cohort to DM and PM patients diagnosed in the
years stated to allow time for subsequent diagnoses to occur.) The
effect of any diagnostic misclassification in relation to DM or PM
would be to decrease our estimates of excess risk. 
In conclusion, we have estimated the long-term risk of cancer
among a population-based cohort of patients with DM or PM. We
found an increased risk of cancer following the diagnosis of DM
and PM, which was significantly raised for females, and for DM
patients aged between 45 and 75 years, and PM patients aged 15
to 44 years. The elevated risk of cancer was seen within the first
3 months for patients with PM and the first 2 years for patients
with DM. A high index of suspicion for malignancy is justified
for patients with DM (approximately 20 new cases per annum in
Scotland), particularly during the first 2 years after diagnosis,
and to a lesser extent PM (approximately 28 new cases per
annum in Scotland), in the first year following diagnosis. 
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